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ABSTRACT 
 
 
Approximately 48% of Americans use prescription drugs within each 30-day 
period, and there are signs this trend is increasing. Although many studies track 
pharmaceuticals’ fates in contaminating waterways, only fairly recent efforts have 
examined the potential impacts of these drugs on non-target organisms. The antibiotics 
sulfamethoxazole and trimethoprim, often prescribed together to treat bacterial infections, 
have been detected worldwide in marine and estuarine environments at concentrations up 
to 700-800 ng/L each. Toxic effects of these drugs have been identified in freshwater 
organisms, with synergistic effects observed in short-term studies of mixtures of the two; 
however, little research has examined possible sub-lethal and longer-term effects of 
antibiotics in environmentally-relevant mixture concentrations on marine organisms. I 
examined the long-term effects of mixtures of these two antibiotics in species of a marine 
system: marine microalgal species, and marine mussels, to determine whether the levels 
currently present in waterways affect organism health and reproduction. 
Microalgal species may be among the most sensitive organisms to pharmaceutical 
contaminants based on ecotoxicity research. I exposed three species of marine microalgae 
(Isochrysis galbana, Chaetoceros neogracile, and Nannochloropsis oculata) to 
environmentally-relevant mixtures of sulfamethoxazole and trimethoprim and examined 
their three-week growth rates. I found that for each species, the antibiotic treatments 
significantly suppressed algal growth. Specifically, I found that sulfamethoxazole was a 
driving factor in suppression of C. neogracile and I. galbana growth, while N. oculata 
responded more sensitively to a broader range of treatment mixture levels, which also 
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included trimethoprim-only treatment groups and mixtures. These results on marine 
microalgae address critical data gaps, and identify the impacts of pharmaceuticals on 
marine primary producers, which could have direct ecosystem implications to higher 
trophic levels. 
Antibiotic pharmaceuticals can also affect marine mussel health, based on 
previous study of sub-cellular endpoints. I hypothesized that the important benthic 
foundational species, the Mytilus californianus mussel, would be significantly impacted 
by long-term 12-week exposure to environmentally-relevant concentrations and mixtures 
of sulfamethoxazole and trimethoprim. Specifically, I measured growth rate, feeding rate, 
condition index, and gonando-somatic index as indicators of whole-organism and 
reproductive health. Sulfamethoxazole concentrations, in particular, and trimethoprim to 
a lesser extent, suppressed mussel growth and significantly affected condition index and 
gonandosomatic index over time. The results of this study offer an understanding of how 
an intertidal system responds to chronic presence of antibiotic mixtures in the water, and 
a more complete picture of the environmental consequences of pharmaceutical 
contaminants released into marine ecosystems at ever-growing rates. 
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Chapter 1: Introduction 
From 2009-2012, 48.7% of Americans used prescription drugs within any 30-day 
period, and data indicate this trend is increasing (Gu et al. 2010, National Center for 
Health Statistics 2015). Prescription drugs are a profitable and rapidly growing industry 
in the US, with spending on all prescription drugs totaling $234.1 billion in 2008 (more 
than double the amount spent in 1999), and currently estimated at approximately $300 
billion (Guo 2015, World Health Organization 2016). This figure is expected to grow to 
$400 billion within just three years (World Health Organization 2016). Approximately 
31% of Americans use two or more prescription drugs in a given 30-day period, with one 
in five children, and nine out of 10 elderly people taking drugs during any 30-day period. 
For antibiotic prescription drugs in particular, four out of five Americans (80%) use 
antibiotics at least once a year (Gu et al. 2010). West Virginia, the state with the highest 
usage rate of antibiotics, reported 1,222 prescriptions for antibiotics per every 1,000 
people during 2007; thus, some Americans are receiving multiple antibiotic prescriptions 
per year (CDDEP 2011).  
These pharmaceuticals, which are widely used in both human and veterinary 
medicine, find many pathways into the environment (Boxall 2004). Many pharmaceutical 
compounds are not fully metabolized by the human body, remaining biologically active 
in waste. In turn, onsite and wastewater treatment plant systems fail to remove all 
pharmaceuticals before releasing effluent water into the environment. Moreover, 
improper disposal of expired or unneeded pharmaceuticals, industrial emissions, and 
agricultural uses (e.g., antibiotic use in aquaculture) also contribute to environmental 
pollution (Boxall 2004). As a result, a vast array of pharmaceuticals has been detected in 
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marine and freshwater organisms, sediments, and waters at high ng/L levels, and even in 
drinking water, with potential unintended effects on non-target organisms and food webs 
(Daughton and Ternes 1999). The threat of antibiotic resistance developing due to 
environmental exposure to antibiotics and antimicrobials has also caused increasing 
concern regarding the growing resistance of pathogenic bacteria in the environment, and 
this is a problem that will likely persist and potentially worsen (Kümmerer 2004). 
In examining the body of research assessing pharmaceutical effects on aquatic 
organisms, there are numerous trends in the type of frequently undertaken studies as well 
as clear data gaps. Trends in this field include freshwater organism-focused studies, 
assessing acute toxicity of pharmaceuticals at high concentrations (greater than 
occurrence data concentrations), and employing short-term exposures (on the order of 
hours to days), with single-drug studies. The identified data gaps represent the contrast of 
many of these factors: marine organism-focused studies are markedly lacking, and also 
studies assessing sub-lethal responses to chronic or longer-term exposures (on the order 
of weeks to months) at lower concentrations (Gaw et al. 2014). Additionally, potential 
mixture effects of pharmaceuticals have been recognized as vitally important as they 
more closely simulate real-world exposures than single-drug studies (Christensen et al. 
2006). With the ever-fluctuating cocktails of low levels of pharmaceuticals in waterways, 
systematic mixture studies are needed to parse out unknown synergisms. González-
Pleiter et al. (2013) found from their tests using antibiotic mixtures on freshwater 
organisms, “it can be concluded that certain specific combinations may pose a potential 
ecological risk for aquatic ecosystems with the present environmentally measured 
concentrations.” 
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Current lack of management action on behalf of governing bodies in the form of 
preventative measures to lessen impacts of pharmaceutical contaminants may be due to 
the fact that the concentrations in which these drugs are detected are often a small 
fraction of typical prescribed therapeutic doses for humans and animals. Thus, they are 
deemed a low risk to human health, and the World Health Organization (2016) notes that 
any form of water safety improvements draws on limited funds and resources that need to 
be prioritized based on potential negative impacts to human health. The WHO states that 
the implementation of pharmaceutical removal techniques would be extremely costly and 
is not currently considered necessary, as there would be a limited human health benefit 
(WHO 2016). However, this perspective neglects any sort of ecological implications, and 
perhaps dampens the impetus by policymakers or the pharmaceutical industry to make 
improved awareness of proper disposal techniques to the public a goal within their 
influence spheres.  
Pharmaceuticals are specifically designed to elicit a biological response at low 
levels, so even low concentrations could impose negative effects on both target and non-
target organisms. The antibiotics sulfamethoxazole (SMX) and trimethoprim (TRI) are 
often prescribed together to treat a suite of bacterial infections. In a 5:1 ratio, they 
comprise the antibiotic drug Bactrim, which is on the World Health Organization’s List 
of Essential Medicines (WHO 2015). Their mode of action is inhibiting synthesis of the 
bacterial enzyme tetrahydrofolic acid, a folic acid derivative (Boothe 2015); however, 
they interrupt the synthesis chain at two different points, leading to synergistic effects in 
combination due to their different target sites (Eguchi et al. 2004). SMX and TRI have 
been commonly detected worldwide in marine and estuarine environments, at 
 
4 
concentrations up to 870 ng/L for trimethoprim, and 765 ng/L for sulfamethoxazole (Gaw 
et al. 2014). Toxicity of these drugs has been identified in freshwater organisms, with 
acute synergistic effects observed in mixtures of the two (Eguchi et al. 2004); however, 
little research has been conducted examining possible sub-lethal effects on marine 
organisms with chronic exposure (weeks to months) at environmentally-relevant 
concentrations. 
For my MS research project, I examined effects of these two commonly-detected 
antibiotics in all mixture combinations including environmentally-relevant high, low and 
control levels on (1) 3-week marine microalgal growth rates for Isochrysis galbana, 
Chaetoceros neogracile, and Nannochloropsis oculata and (2) 12-week intertidal marine 
mussel, Mytilus californianus growth rates, feeding rates, and reproductive and condition 
indices (Figure 1). In separate simulations using a laboratory temperature/ light-
controlled tank set-up, I measured these endpoints to parse out independent effects; I also 
consider potential interactive trophic effects within the food chain. I hypothesize that, 
based on the known microalgal sensitivities to pharmaceuticals, documented mussel sub-
cellular immuno-sensitivity health responses to antibiotics, and the synergistic nature of 
SMX and TRI, algal growth over time will be suppressed, and growth and health 
indicators of marine mussels will be suppressed (Isidori et al. 2005, Guo et al. 2015, 
Lacaze et al. 2015, Figure 1).  An understanding of how a representative intertidal system 
responds to chronic exposure of SMX and TRI mixtures offers a more complete picture 
of the environmental consequences antibiotic pharmaceuticals have when released into 
marine ecosystems at ever-growing rates, and sheds light on the potential for cascading 
trophic effects. 
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Figure 1.1 Conceptual model of knowns, questions, and hypotheses framing this thesis 
investigating long-term effects of pharmaceutical contaminants on marine intertidal 
species. 
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Chapter 2: Effects of antibiotics mixtures at environmentally-relevant 
concentrations on marine microalgae  
 
 
Introduction 
Photosynthetic algae are part of the base of the food web in aquatic ecosystems, 
and population level alterations to these photoautotrophic organisms can result in 
quickly-realized and severe bottom-up effects at higher trophic levels (Nie et al. 2013). 
Thus, microalgae are often used as indicators of pollution and water quality (McCormick 
and Cairns Jr. 1994). Pharmaceuticals, which are widely used in both human and 
veterinary medicine, follow many documented pathways into the environment and may 
be significant stressors to organisms (Boxall 2004).  
Pharmaceutical compounds are often not fully metabolized by the human body, 
remaining biologically active in waste. In turn, onsite and wastewater treatment plant 
systems fail to remove all pharmaceuticals before releasing effluent water into the 
environment. Moreover, improper disposal of expired or unneeded pharmaceuticals, 
industrial emissions, and agricultural uses (e.g., antibiotic use in aquaculture) also 
contribute to environmental pollution (Boxall 2004). As a result, a vast array of 
pharmaceuticals has been detected in marine and freshwater organisms, sediments, and 
waters, including drinking water, at concentrations of high ng/L with potential 
unintended effects on non-target organisms and food webs (Daughton and Ternes 1999). 
Aquatic studies of pharmaceutical effects on microalgae have focused on acute 
toxicity of freshwater microalgae, with most experimental tests completed within 96 
hours (Halling-Sørensen 2000, Cleuvers 2003, Eguchi et al. 2004, El-Bassat et al. 2012, 
González-Pleiter et al. 2013). There is a lack of chronic effects studies using 
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environmentally-relevant concentrations of drugs. In several studies of pharmaceutical 
drugs applied to multiple freshwater organisms (such as algae, Daphnia, fish, and 
amphibians), the drugs exhibited the greatest effects on freshwater microalgae (Isidori et 
al. 2005, El-Bassat et al. 2012). Isodori et al. (2005) found that out of the six antibiotics 
studied, most were bioactive at concentrations in the order of µg/L, mainly for freshwater 
algae, and the drugs were one or two orders of magnitude less active in rotifers and 
crustaceans. Thus, microalgae may be among the most sensitive aquatic organisms to 
antibiotics. 
Antibiotics target bacteria rather than eukaryotic algae, but these drugs may also 
cause detrimental effects to algae, as some algal organelles (such as the chloroplast and 
mitochondria) retain similarities to bacteria in structure and evolutionary origin (Vannini 
et al. 2011, Guo et al. 2015). Many organisms also have complex interactions with 
bacteria, and the application of low-levels of antibiotics over the long term may disrupt 
these interactions, leading to the suppression of population growth rates and potential 
effects on the availability of algae as a food source for higher trophic levels. Guo et al.’s 
(2015) review of the pharmaceutical risks to primary producers found that some 
antibiotics could pose a potential threat to algal species, with blue-green and green algae 
being particularly sensitive. However, they note many unstudied aspects of 
pharmaceutical risks, such as pharmaceutical mixture effects on algal species to identify 
interactive effects, and the need for studies of long-term effects of pharmaceuticals at 
environmentally-relevant concentrations (Guo et al. 2015). 
Pharmaceutical exposure studies on marine organisms are notably lacking (Gaw 
et al. 2014). In the present study, I examine the growth response of three marine 
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microalgal species to treatment at environmentally-relevant levels of antibiotic mixtures 
of sulfamethoxazole (SMX) and trimethoprim (TRI). Sulfamethoxazole and trimethoprim 
are often prescribed together to treat a suite of bacterial infections. In a 5:1 ratio, they 
comprise the antibiotic drug Bactrim, which is on the World Health Organization’s List 
of Essential Medicines (WHO 2015). Their mode of action is inhibiting synthesis of the 
bacterial enzyme tetrahydrofolic acid, a folic acid derivative (Boothe 2015); however, 
they interrupt the synthesis chain at two different points, lending to synergistic effects in 
combination due to their different target sites (Eguchi et al. 2004). Worldwide, SMX and 
TRI have been commonly detected in marine and estuarine environments at 
concentrations up to 870 ng/L for trimethoprim and 765 ng/L for sulfamethoxazole (Gaw 
et al. 2014). Toxicity of these drugs has been identified in freshwater organisms, with 
acute synergistic effects observed in mixtures of the two (Eguchi et al. 2004); however, 
little research has examined possible chronic exposure (weeks to months) effects on 
marine microalgae at environmentally-relevant concentrations. These low-level 
concentrations and antibiotic mixtures more closely mimic real-world exposures.  
Isochrysis galbana, Chaetoceros neogracile, and Nannochloropsis oculata are all 
eukaryotic marine microalgal species commonly cultured for use in rearing marine 
organisms such as bivalves, shrimp, and fish (Spolaore et al. 2006). Characteristics such 
as nutritional requirements for the predator, sufficient cell sizes and digestibility of the 
microalgae, reproduction rate, and reliable and sustainable culturing in standardized 
commercial growing systems all determine their applicability in the rearing of different 
marine organisms. Among the three species, N. oculata and C. neogracile are both within 
Phylum Heterokontophyta, which contains more than 25,000 species (of mostly algae) 
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and are thus most closely related evolutionarily. C. neogracile is a centric non-chain 
forming marine diatom, 6-9µm in width and 2-3µm in length, in the class 
Bacillariophyceae. N. oculata, is in the class Eustigmatophyceae and differs from other 
related microalgae in that it has chlorophyll a and completely lacks chlorophyll b and c 
(Simionato et al. 2013). Compared to closely related taxa, N. oculata are smaller, with a 
diameter of 2 to 3 µm and have a simple structure with reduced structural elements 
(Simionato et al. 2013). I. galbana is in Phylum Haptophyta, which is characterized by a 
unique organelle, the haptonema. I. galbana is a single-celled marine microalgal species 
ranging in length from 3-6 µm and is found in a wide geographic range, including in the 
northeastern Pacific. I. galbana has commonly been used as an indicator species among 
primary producers in aquatic food chains and ecosystems (Lai et al. 2009). Huang et al. 
2014 found the sulfonamide drug, sulfamonomethoxine, exhibited greater toxicity to I. 
galbana than to Daphnia and fish, and concluded that this drug could be a risk to aquatic 
organisms in waters. These species reproduce asexually by cell division in the presence 
of proper light and nutrient conditions.  
This study tested the hypothesis that exposure to SMX and TRI over the course of 
several weeks would significantly suppress algal growth due to the sensitivities of 
microalgae to pharmaceuticals, and that these effects would be more pronounced in 
mixture treatments, and at higher concentrations, due to the documented synergistic 
nature of the two drugs. 
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Methods 
Algal Cultures 
The marine microalgal species, Isochrysis galbana and Chaetoceros neogracile 
were provided by B. Schoolfield and K. Preston from the Hatfield Marine Science 
Center, Newport, OR, while Nannochloropsis oculata was purchased from Mercer of 
Montana, LLC. All three species were cultivated in 33 ppt seawater, prepared by adding 
synthetic sea salt (Instant Ocean) to deionized water and adjusting the solution to 33 ppt; 
essential Proline F/2 algal nutrients were added (with sodium metasilicate also added in 
recommended quantities for the diatom C. neogracile) (Price et al. 1989, Rebolloso-
Fuentes et al. 2001). Algae were grown at 15 ± 1 °C under a 12 hr light/dark illumination 
cycle with daily gentle shaking utilizing four 32-watt natural full-spectrum bulbs with 
2850 lumens each.  
Antibiotics  
Sulfamethoxazole and trimethoprim were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Stock solutions of each antibiotic were prepared by dissolving the 
selected antibiotic in deionized water, and concentrations of each antibiotic were then 
adjusted from each stock solution using serial dilutions, with negligible volumes of 30-34 
µl added to each experimental jar every 10 days to mimic effluent pulses. The half-life 
for primary degradation of trimethoprim in waters is estimated to be >42 days, and for 
sulfonamide drugs >21 days (Kümmerer 2008). 
Pilot study 
An exploratory pilot study was performed prior to the full experiment to test the 
ability of I. galbana to grow in the proposed laboratory set-up, and to test a cell density 
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measuring technique involving microscope slide hemocytometers. I determined that the 
algae did in fact grow steadily in the laboratory over a period of several weeks before 
populations crashed in the pilot study, but that the lighting was not sufficiently uniform 
throughout the tank. Also, the cell counts could be assessed via microscope slides, but the 
time required to perform this counting method was deemed infeasible for this set-up. As a 
result of this pilot study, I changed the lighting set-up to achieve uniformity throughout 
the tank, and I explored the use of an automated hemocytometer to perform algal cell 
counts, which vastly improved feasibility. 
Experimental Design 
Algae growth rates over time were measured in response to a treatment plan 
comprised of control, low, and high SMX and TRI levels in a 3x3 factorial design. High 
and low antibiotic concentrations were determined based on Gaw et al. (2014) averages 
of worldwide occurrence data (Table 2.1). For worldwide occurrence data, the high and 
low ranges of the two drugs were averaged for all reported instances in which both were 
present to arrive at the test concentrations (Gaw et al. 2014) (Table 2.1). Nine replicate 
jars of each of the nine treatments were included in the study. Experimental tests were 
performed using 16-oz glass jars containing 350 ml of seawater, comprised of Instant 
Ocean with Proline F/2™ algal nutrients at manufacturer recommended levels. The algal 
inocula were taken from homogenized cultures and added to 350 ml of test solution to 
obtain initial cell densities. The jars were covered with perforated translucent covers to 
prevent evaporation and contamination, but gas exchange was allowed. The jars were 
gently shaken once a day. Treatments were randomly distributed within a water bath 
maintained at 15 ± 1 °C and under a 12 hr full spectrum light/dark illumination cycle. 
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Cell growth lasted for 12 to 15 days for I. galbana (with counts taken for 19 days), and 
21 days for C. neogracile and N. oculata and was measured at 3-day intervals. The cell 
density of algae was counted by an automated hemocytometer (Beckman Coulter 
Counter, dual threshold) once every 3 days, for which 100 µl of the test medium was 
extracted from each jar. Growth curves of cell density over time were set up to determine 
species-specific rates of algal population growth over 20 days.  
Table 2.1. Antibiotic mixture treatment concentrations (high and low values are based off 
of worldwide occurrence data range averages). The 9 treatment levels (grey) are 
comprised of control (0), low, and high levels in every combination. For each treatment, 
n=9. SMX = sulfamethoxazole, TRI = trimethoprim, with bold indicating SMX levels. 
SMX  
0 7.5	  ng/L	  (Low)	   75	  ng/L	  (High) 
0 0	  -­‐	  0 Low	  –	  0 High	  -­‐	  0 
8.5	  ng/L	  (Low) 0	  -­‐	  Low Low	  –	  Low High	  -­‐	  Low 
 
 
TRI 
85	  ng/L	  (High) 0	  -­‐	  High Low	  -­‐	  High High	  -­‐	  High 
 
Statistical analysis 
Algal data were analyzed with R studio software version 0.98.1062 including the 
package “ez” to calculate repeated-measures analysis of variance (ANOVA) to analyze 
differences in each algal species’ population growth at sampling days throughout the 
testing period (R Development Core Team 2008, Lawrence 2015). Treatment categories 
and sampling date were factors with tanks included as an error term to account for the 
non-independence between temporal samples. The assumption of sphericity was 
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determined for each factor using the Mauchly test and adjusted using Greenhouse-Geisser 
corrections. Differences in beginning concentrations were accounted for by standardizing 
to Day 0 concentrations prior to analysis. Population growth rates during the growth 
phase for each algal species were analyzed. Interaction plots of final algal counts were 
generated to parse out interactive drug effects when significant. Normality and 
homogeneity of variances were assessed through graphical inspection of the model 
residuals, and data were square-root (for C. neogracile and I. galbana) or log-
transformed (for N. oculata) to meet these assumptions. Post-hoc significant differences 
between treatments and controls were measured with a pair-wise Tukey test. Values were 
considered significantly different at p<0.05.  
 
Results  
Algal cell density grew over time in three species of marine microalgae, but was 
suppressed at higher levels of SMX for all species (Figure 2.1A-C). Treatments with 
higher levels of SMX resulted in lower algal cell density over time for C. neogracile and 
I. galbana and all but one treatment mixture concentration resulted in lower cell densities 
over time for N. oculata as compared to the control (Figure 2.1, Table 2.2).  
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Figure 2.1. Results of the growth phase of algal cell density treatment averages for A) I. 
galbana, B) C. neogracile and C) N. oculata, averaged by antibiotic mixture treatment 
levels, and standardized by Day 0 concentrations. For each treatment, n=9 (except for S2-
T2 for I. galbana, where n = 8). Error bars indicate ± SE of the mean. 
 
The interaction of SMX level and time had a significant suppressive effect on the growth 
of all three algal species, while the interactive effect of TRI and time also had a 
significant suppressive effect on N. oculata only (Table 2.2; Figure 2.2). N. oculata 
responded most sensitively to the treatments with both SMX and TRI treatment levels 
suppressing algal growth, although there was no significant interactive effect of the two 
drugs (Table 2.2; Figure 2.1). The interactive effect of SMX and TRI over time was 
significant for I. galbana, driven by the fact that the S0-T1 treatment growth averages 
C 
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were significantly higher than the other treatments, but overall, SMX level was a stronger 
significant suppressive factor, F71,284 = 5.66, p = 0.005 (Table 2.2).  
Table 2.2. Repeated-measures ANOVA results of algal growth for three algal species. 
Significant factors and P-values < 0.05 are shown in bold.  
Algae 
Species Factor SS MS df F p 
SMX 6.27E+12 3.13E+12 2 5.66 0.005 
TRI 6.77E+11 3.39E+11 2 0.61 0.545 
Sample Date 8.44E+14 4.22E+14 2 1862.14  <
 0.001 
TRI*SMX 1.79E+12 4.47E+11 4 0.81 0.524 
SMX * Sample Date 2.26E+12 5.64E+11 4 2.49 0.013 
TRI * Sample Date 9.23E+11 2.31E+11 4 1.02 0.422 
TRI * SMX * Date 3.47E+12 2.17E+11 16 1.91 0.019 
Error among groups 3.93E+13 5.53E+11 71 
 
 
 
Isochrysis 
galbana 
Error within groups 3.22E+13 1.13E+11 284 
 
SMX 1.11E+14 5.55E+13 2 7.55   0.001 
TRI 1.43E+11 7.15E+10 2 0.97 0.383 
Sample Date 2.28E+14 3.26E+13 7 1154.16 <0.001 
TRI*SMX 2.12E+14 5.30E+13 4 0.07 0.990 
SMX * Sample Date 9.38E+11 6.70E+10 14 2.38 0.003 
TRI * Sample Date 2.66E+11 1.90E+10 14 0.67 0.800 
TRI * SMX * Date 5.97E+11 2.13E+10 28 0.76 0.814 
Error among groups 5.27E+12 7.43E+10 72 
 
 
 
 
Chaetoceros 
neogracile 
Error within groups 1.42E+13 5.00E+10 504 
 
SMX 1.79E+13 8.93E+12 2 19.70 <0.001 
TRI 2.30E+12 1.15E+12 2 2.54 0.086 
Sample Date 2.82E+14 4.03E+13 7 522.69 <0.001 
TRI*SMX 1.85E+12 4.62E+11 4 1.02 0.403 
SMX * Sample Date 9.50E+12 6.79E+11 14 8.81 <0.001 
TRI * Sample Date 3.54E+12 2.53E+11 14 3.28 <0.001 
TRI * SMX * Date 2.85E+12 1.02E+11 28 1.32 0.126 
Error among groups 3.26E+13 4.60E+11 72 
 
 
 
 
Nannochloropsis 
oculata 
Error within groups 3.88E+13 1.37E+11 504 
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Figure 2.2. The growth phase of algal cell density for A) I. galbana, B) C. neogracile and 
C) N. oculata in response to the treatment plan, averaged by the SMX concentrations 
(neglecting TRI concentrations) and standardized by Day 0 concentrations. For each 
SMX treatment, n = 27 (except for A, S2: n = 26). Error bars indicate ± SE of the mean. 
A 
B 
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Discussion 
This study demonstrates that prolonged exposure to environmentally-relevant 
concentrations of two antibiotics affects algal population growth rates over time. When 
three species of marine microalgae from two Phyla were monitored over a ~three week 
exposure period to better understand how each species responds to mixtures of 
antibiotics, the compounds and compound combinations that affected algal population 
growth differed across species. However, SMX concentration was a significant 
suppressive factor for all three species (with the interaction with time being significant 
for all). N. oculata was the most sensitive of the three species with TRI also suppressing 
growth rates and with seven treatment mixture combinations significantly lowering 
growth. This research builds on previous studies and addresses a prior data gap of 
identifying chronic exposure effects of antibiotic mixtures at environmentally-relevant 
levels. By simulating chronic antibiotic mixture exposure in the laboratory, I offer a 
glimpse into how these emerging contaminants may impair primary producers in marine 
waters exposed to these drugs, possibly imposing bottom-up effects on marine 
communities. 
SMX concentrations were the main driver of algal reproduction suppression for 
two of the species, while N. oculata, with the most simplified cell structure (Simionato et 
al. 2013), was significantly affected by both SMX and TRI. Perhaps due to chemical 
characteristics of the drugs such as solubility or degradation products, or perhaps due to 
different microalgal species’ cellular structure, even species with a similar evolutionary 
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lineage can exhibit differential sensitivities to pharmaceutical contaminants within the 
same class (Guo et al. 2015). Thus, it is important to investigate long-term full factorial 
testing on mixtures of pharmaceuticals with multiple organisms.  
SMX may have had a greater effect on algal growth than TRI due to the potential 
increased toxicity of the photo-degradation products of SMX in seawater (Trovó et al. 
2009b). In studies of the degradation processes and products of both SMX and TRI, it has 
been found that both chemicals are not readily biodegradable in seawater, but they 
transform primarily through photo-degradation, which is considerably slowed in saltwater 
than in freshwater (with a half-life of approximately 42 days for trimethoprim and 21 
days for sulfonamide drugs in seawater) (Benotti and Brownawell 2007, 2009, Kümmerer 
2008, Larcher and Yargeau 2012). There has been little study of the ecological risks of 
the photo-degradation products that form, but there is some indication that these products 
retain the activity of the parent molecule to elicit a toxicological effect on non-target 
organisms in the environment, which, in some cases, is greater than the toxicity of the 
parent molecule. Trovó et al. (2009a) found that over the course of the testing period, 
despite 45% mineralization in saltwater, toxicity of SMX increased from 16% to 86% in 
Vibrio fischeri bacterium tests, which suggests that the intermediates generated in 
saltwater are potentially more toxic. Additionally, a separate study on this subject (Trovó 
et al. 2009b) found that test organisms showed an increase from 60% to 100% 
immobilization over the course of the test period with SMX, with the authors concluding 
that  there was a higher toxicity of the photo-transformation products generated. 
Trimethoprim photo-degradation studies in saltwater, though limited, indicate “only a 
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small increase” in the toxicity on test organisms, with intermediates which were 
moderately toxic for the organisms tested (Sirtori et al. 2010, Fatta-Kassinos et al. 
2011). Toxicity as well as sub-lethal assessments of transformation products must be 
included in the suite of pharmaceutical contaminant research to more closely simulate 
environmental conditions. 
Marine microalgae possess chloroplast and mitochondrial organelles, retaining 
similarities to bacteria (the target of antibiotics) in structure and evolutionary origin, but 
algae and bacteria have also co-existed for more than 200 million years, resulting in 
complex interactions between them (Vannini et al. 2011, Liu et al. 2012, Guo et al. 
2015). An example of this interaction is that bacteria produce and supply vitamin B12 to 
some diatom species, which is essential for their successful growth (Croft et al. 2005, 
Guo et al. 2015). A range of antibiotics in environmentally-relevant concentrations can 
damage bacteria through dissolution of their membranes or inhibition of essential 
enzymes (Schreiber and Szewzyk 2008, Duggar 2011, Ji et al. 2013). Antibiotics are 
known to damage bacteria experimentally, and it is likely that similar processes are 
occurring in the wild to bacteria that supply nutrients to algal species (Guo et al. 2015). 
Active antibiotics may be indirectly inhibiting algal species by influencing the co-
existing nutrient-supply system between marine microalgae and bacteria, which is 
essential for survival (Croft et al. 2005). 
Primary producers are indispensable elements of food webs and nutrient-cycling 
processes in marine ecosystems; thus impacts of contaminants on microalgae might shift 
the balance of the community (Kümmerer 2008, Guo et al. 2015). Our findings that 
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marine microalgal species may be significantly affected by environmentally-relevant 
concentrations of antibiotic mixtures serve as a foundation to understand how 
pharmaceuticals are affecting marine communities through potential trophic interactions. 
Pharmaceuticals should be considered significant potential stressors to vulnerable aquatic 
organisms already stressed by other environmental factors such as climate change, ocean 
acidification, and rising sea level (Waycott et al. 2009). There is little study of the 
interactive effects of global environmental changes and pharmaceutical toxicity for 
freshwater organisms and no known research for marine organisms (Kim et al. 2010). 
Changes in global climate adds a layer of complication in which cell processes ranging 
from photosynthesis to thermo-regulation are likely to be disrupted, leading to possible 
combined algal reproductive suppression with contaminants. In a world with changing 
climate, increasing coastal populations, and rising pharmaceutical use, marine organisms 
are exposed to an ever-increasing array of pharmaceuticals from different classes and 
with different target sites, some of which are known to negatively impact aquatic 
organisms (Boxall 2004, Gaw et al. 2014, Guo et al. 2015) 
Many of the effects detected would not have been identified if the study had been 
run for the typical experimental periods of hours or days. For example, some algal cell 
density treatment average slopes diverged halfway through the three-week study period 
(and time-drug interactions were significant for all three species), indicating that longer-
term effects of low concentrations of these drugs may be vastly underestimated based on 
typical shorter period exposure trials. Understanding the extent to which antibiotics in 
particular and pharmaceuticals in general affect marine organisms over the long-term will 
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require investigation across more species, drugs, degradation products, and in 
combinations. Future research in the field of pharmaceutical contaminants will require 
focus on these topics to assess basic marine organismal and intra-species effects in order 
to prevent cumulative potential inter-species ecosystem level effects.  
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Chapter 3: Environmentally-relevant concentrations of antibiotic mixtures and 
marine mussel growth, feeding, and reproduction health 
 
 
Introduction 
Pharmaceuticals have many pathways into the environment (through improper 
disposal of drugs, veterinary use, wastewater treatment plant effluent, and aquaculture 
use, for example), and have been detected in the natural environment across landscape 
and waterway types, with many compounds persisting in the environment for months to 
years (Daughton and Ternes 1999, Richardson et al. 2005, Boxall et al. 2012). The result 
of these numerous pathways and the worldwide occurrence is that pharmaceuticals have 
increasingly been recognized as emerging contaminants of concern (Monteiro and Boxall 
2009, Boxall et al. 2012). Although commonly detected at relatively low concentrations 
(ng/L) in the environment compared to medical dosages, pharmaceuticals are designed to 
elicit biological responses on their target sites, and there exist many critical questions 
regarding the effects these low concentrations have over the long term on non-target 
organisms (Boxall et al. 2012). Several decades of research on xenobiotics such as PCBs 
and DDT has demonstrated the hormone-mimicking, non-monotonic effects on the 
reproductive systems of organisms due to exposures to those chemicals in the low ng/L 
range; pharmaceuticals, as biologically-active substances developed with the intention of 
disrupting specific pathways and processes in humans and organisms, must be similarly 
intensively investigated for their potential long-term low-level contaminant impacts 
(Colborn and Clement 1992, Halling-Sørensen et al. 1998, Boxall et al. 2012).  
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Recent studies confirm that pharmaceuticals occur widely in marine and coastal 
environments, but many data gaps in this field exist, including potential risk assessments 
of marine organisms exposed to these drugs at environmentally-relevant levels (Cleuvers 
2003, Gaw et al. 2014). Ecotoxicity studies for pharmaceuticals are commonly performed 
over a relatively short time span (hours to days), utilizing high concentrations of single 
drugs at a time, and assessing lethal endpoints (Láng and Kőhidai 2012, Gaw et al. 2014). 
Antibiotics are among the most frequently detected prescription classes (along with beta-
blockers and anti-inflammatory drugs) found in the environment (Láng and Kőhidai 
2012). The complete environmental risk assessment of antibiotic contaminants on 
organisms is deficient in several categories such as the lack of chronic, long-term data on 
low concentrations, sub-lethal endpoints, and utilizing mixture concentrations. In the 
wild, organisms are not being exposed to one drug at a time; they are exposed to 
continuously-delivered cocktails of pharmaceuticals at low concentrations that may act 
synergistically (Glassmeyer et al. 2008). Bridging the knowledge gap between 
ecotoxicity studies and sub-lethal chronic ecological mixture effects requires a study 
approach of a different length and scope. 
Despite the focus on acute and chronic toxicity to freshwater organisms, there is a 
lack of understanding of how these pharmaceuticals may impact marine organisms (Gaw 
et al. 2014). In the present study, I examine whole-organism responses of marine mussels 
to treatments at environmentally-relevant concentrations of antibiotic mixtures of 
sulfamethoxazole (SMX) and trimethoprim (TRI). The antibiotics sulfamethoxazole 
(SMX), and trimethoprim (TRI) are often prescribed together to treat a suite of bacterial 
infections. In a 5:1 ratio, they comprise the antibiotic drug Bactrim, which is on the 
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World Health Organization’s List of Essential Medicines (WHO 2015). Their mode of 
action is inhibiting synthesis of the bacterial enzyme tetrahydrofolic acid, a folic acid 
derivative (Boothe 2015); however, they interrupt the synthesis chain at two different 
points, lending to synergistic effects in combination due to their different target sites 
(Eguchi et al. 2004). Worldwide, SMX and TRI have been commonly detected in marine 
and estuarine environments, at concentrations up to 870 ng/L for trimethoprim, and 765 
ng/L for sulfamethoxazole (Gaw et al. 2014). Toxicity of these drugs has been identified 
in freshwater organisms, with acute synergistic effects observed in mixtures of the two 
(Eguchi et al. 2004); however, little research has examined possible chronic exposure 
(weeks to months) effects on marine organisms at environmentally-relevant 
concentrations. These low-level concentrations and antibiotic mixtures, more closely 
mimic real-world exposures. 
The California mussel, Mytilus californianus, is an important benthic foundational 
species found along the west coast of North America (Suchanek 1992). These 
invertebrates are efficient filter feeders, able to filter 2-3 liters of water per hour (during 
which they consume marine microalgae as a food source), and they specialize in living in 
large aggregations on rocky substrate in the intertidal and subtidal zones (Suchanek 
1981). Fabbri and Franzellitti (2015) report that caged mollusks are increasingly used to 
investigate pharmaceutical occurrence in coastal environments, since their accumulation 
offers information regarding exposure levels and time. Due to the fact that bivalves are 
filter-feeding and sessile organisms at the substrate-water interface, they are deemed as 
effective sentinels for in-situ monitoring of micro-pollutants (Fabbri and Franzellitti 
2015). For example, the blue mussel (Mytilus edulis) was found to accumulate five 
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pharmaceuticals in a 6-month caging experiment off the Belgian coast (Fabbri and 
Franzellitti 2015). McEneff et al. (2014) reported the occurrence of 5 pharmaceuticals 
(including trimethoprim) in marine mussels during a 1-year long caging experiment along 
the Irish coastline, with most of the five drugs found in mussel tissues also detected in 
surface waters at average concentrations in the mid to high ng/L. 
The potential toxicity and sub-lethal effects of pharmaceuticals in general and 
antibiotics in particular on aquatic invertebrates is still poorly understood (Lacaze et al. 
2015). For marine organisms, there are a lack of studies on whole-organism sub-lethal 
effects and a lack of chronic exposure studies using environmentally-relevant 
pharmaceutical concentrations. Lacaze et al. (2015) showed that antibiotics affect the 
immune system of the blue mussel, Mytilus edulis, utilizing genotoxic and immunotoxic 
endpoints. There is a focus in this field on sub-organismal assessment methods, where the 
effects of pharmaceutical exposure on freshwater and marine bivalves are at the 
molecular level, such as disturbed enzyme functions, DNA damage, and modulated gene 
expression (Franzellitti et al. 2013, Gonzalez-Rey and Bebianno 2013, Lacaze et al. 
2015). There are also cellular level studies, with assessments of increased oxidative 
stress, cytotoxicity and immunotoxicity (Gust et al. 2012, Tsiaka et al. 2013, Lacaze et al. 
2015).  
Many organisms have complex interactions with bacteria (which play a role in 
digestion across taxonomic groups (Eckburg et al. 2005), and it has been demonstrated 
that pharmaceutical target sites in humans may have counterparts which could be present 
in invertebrates, and possibly affect comparable pathways (Christen et al. 2010). Building 
on this, I examined the response of marine mussels in the form of growth and mass, algal 
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clearance rates, and condition and reproductive indices to environmentally-relevant 
mixtures of the antibiotics sulfamethoxazole (SMX) and trimethoprim (TRI). I 
hypothesize that these tissue-level and whole-organism level marine mussel metrics will 
be impacted by prolonged exposure to these drugs, and that interactive effects will be 
apparent in mixture concentrations. The hypothesis is that antibiotic treatments will 
interfere with M. californianus algal feeding rates or digestion, and will result in overall 
suppression of growth, mass, condition index, and gonado-somatic index in the higher 
treatment levels. I hypothesize that the effect may be more pronounced in mixture 
treatments of the drugs, due to the documented synergistic effects of SMX and TRI on 
organisms in combination (Nord et al. 1974). This study targets data gaps in emerging 
antibiotic pharmaceutical contaminants research: 1) mixture effects of pharmaceuticals 
which are known to act synergistically, 2) the impacts to whole organism physiology and 
function; 3) the effects of long-term exposure periods (on the scale of months) 4) effects 
of environmentally-relevant levels. 
 
Methods 
Study Organisms and Acclimation Conditions 
Approximately 750 marine mussels (Mytilus californianus) between 1.5 and 2.8 
cm in length were collected on September 7, 2015 from Rockaway Beach in Tillamook 
County, Oregon. Mussels were first grouped for 1 week in 23 liters of Instant Ocean 
seawater in a tank with 32 parts per thousand (ppt) salinity, and water quality was 
monitored to ensure appropriate ammonia, nitrite, nitrate, and pH conditions. Mussels 
were randomly distributed to test jars to acclimatize for 2 weeks, with 9 mussels per 16 
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oz. jar, in 400 ml of water. Throughout the experiment, mussels were kept in Instant 
Ocean seawater pre-treated with ammonia, nitrite, and nitrate reducers to maintain tank 
environments. 
Experimental Design 
Experimental tests were performed over 12 weeks using 16-oz glass jar tanks 
comprised of Instant Ocean seawater maintained at 32 ppt salinity. Mussels jars were 
kept in a 15 ± 1 °C water bath, using a 12 hr light/dark illumination cycle with 24 
hour/day aeration. There were four 32-watt natural full-spectrum bulbs with 2850 lumens 
each over the water bath. The 81 jars had full water changes every 10 days, and were 
treated according to an antibiotic treatment plan, consisting of control, low and high 
concentrations of SMX and TRI antibiotic concentrations determined based on Gaw et al. 
(2015) averages of worldwide occurrence data, in a 3x3 factorial design (Table 3.1). With 
the worldwide occurrence data, the high ranges were averaged and the low ranges were 
averaged of SMX and TRI individually for all reported instances in which both were 
present to arrive at the test concentrations (Table 3.1) (Gaw et al. 2014). These antibiotic 
mixture treatments were applied every 10 days (mimicking effluent pulse effects) 
following the full water changes, with nine replicate jars for each mixture treatment 
concentration described in Table 3.1.  
 Each jar began with 9 mussels per jar, and 3 mussels were sub-sampled from 
each jar at week 6 in order to measure tissue indices. A background mortality rate of less 
than 3.6% was experienced throughout the duration of the 12-week experiment. All 
Instant Ocean seawater was pre-treated with ammonia, nitrite, and nitrate reducers to 
maintain tank environments, and ammonia, nitrite, nitrate, pH, and salinity levels were 
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monitored in random jar checks during specified points during the water change cycle. To 
ameliorate unavoidable evaporation across jars and improve water quality, every 5th day 
between water changes, 50 ml of slightly under-salinated (29 ppt) saltwater was added to 
all jars to bring jar levels up to 400 ml and proper salinity. Every 3 days, mussels were 
fed non-viable Isochyris galbana algae based on Reed Mariculture’s™ feeding guidelines 
with feeding volume scaled by the number of mussels per jar at any given time.  
Table 3.1. Antibiotic mixture treatment concentrations (high and low values are based off 
of worldwide occurrence data range averages). The 9 treatment levels (grey) are 
comprised of control (0), low, and high levels in every combination. For each treatment, 
n=9. SMX = sulfamethoxazole, TRI = trimethoprim, with bold indicating SMX levels. 
SMX  
0 7.5	  ng/L	  
(Low) 
75	  ng/L	  (High) 
0 0	  -­‐	  0 Low	  –	  0 High	  -­‐	  0 
8.5	  ng/L	  (Low) 0	  -­‐	  Low Low	  –	  Low High	  -­‐	  Low 
 
 
TRI 
85	  ng/L	  (High) 0	  -­‐	  High Low	  -­‐	  High High	  -­‐	  High 
 
 
Antibiotics 
Sulfamethoxazole and trimethoprim were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Stock solutions of each antibiotic were prepared by dissolving the 
selected antibiotic with deionized water, and concentrations of each antibiotic in 
experimental tests were then adjusted from each stock solution using serial dilutions, 
allowing for a negligible volume of 30-34 µl added to each jar every 10 days, to mimic 
 
30 
effluent pulses. The half-life in water for primary degradation of trimethoprim is 
estimated to be >42 days, and for sulfonamide drugs is >21 days (Kümmerer 2004). 
Endpoints 
In response to the antibiotic treatment levels applied, various endpoints were measured in 
the mussels throughout the 12-week experiment (Table 3.2) 
Table 3.2. Endpoints measured in test mussels in response to treatment of antibiotics 
SMX and TRI mixtures. 
Endpoints Measured 
 (in response to treatments) 
Frequency 
Growth rates: dimensions (L, W, H), mass Week 0, 6, 9, 12 
Feeding rates (algal clearance) Week 2, 4, 6, 8, 10, 12 
Condition Index (CI),  
Gonado-Somatic Tissue Index (GSI) 
Week 6, 12 
 
Mussel Growth 
To examine differences in growth rates over time, all mussels in the experiment 
were measured in three dimensions using calipers (Mitutoyo 500 196-30) accurate to 
±0.01 mm, and were massed using a balance accurate to ±0.001 grams (Southern 
Laboratories) (Suchanek 1981). Length here is defined as the maximum anterior (umbo) 
dimension to the posterior dimension, height as maximum dorsal-ventral dimension of 
the shell measured perpendicular to the hinge, and width as the maximum left-right 
dimension with both valves appressed (Larson et al. 2014). These measurements were 
taken at weeks 0, 6, 9, and 12 (at the end of the experiment). Percent change in 
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dimensions was calculated as % change =  (Dimensiont – Dimension0)/Dimension0)) * 
100 for each dimension measurement for time “t” as compared to initial time “0,” and the 
response variable approximation of mussel shell volume (mm3) was taken as Length * 
Width * Height of each mussel at each sampling event. At week 6 sampling, within-tank 
means are comprised of 9 mussels per tank, and at weeks 9 and 12, 6 mussels per tank (as 
mussels were subsampled at week 6). 
Feeding Rates 
Following the methods of Berg et al. (1996) for measuring mussel feeding rates 
(algal clearance), three randomly selected jars per treatment level were monitored 
biweekly, and algal cell densities within the jars were measured with a Beckman Coulter 
Counter at two time points: 1) just after feeding, and 2) approximately 2-3 hours post-
feeding to determine the uptake rate by the filter-feeding mussels. Exact time is 
accounted for (in # of minutes) in the equation: Clearance rate = [(lnC0 – lnCt) – (lnC’0 – 
lnC’t)] * V / t, where C0 = algal concentration at the start of the test period, Ct = algal 
concentration at the end of the test period, C’0 = algal concentration of the control jar at 
the beginning of the experiment, C’t = algal concentration of the control jar at the end of 
the test period, V = experimental volume, and t = time (minutes). Clearance rates were 
divided by the number of mussels per jar at each sampling event to obtain a per mussel 
average. Control jars with algae added but without mussels were measured to identify 
algal settling rates on the glassware. Randomly selected jars were also measured to 
confirm that pre-feeding background rates of particles within the same size class were not 
significant in these particle counter measurements. 
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Body condition: Gonado-somatic Index & Condition Index  
Methods for measuring gonado-somatic index (GSI) and mussel condition index 
(CI) are based on Schiedek et al. (2006). At week 6, three mussels from each jar were 
sub-sampled and frozen to measure CI and GSI (for reproductively mature mussels), and 
again at week 12. The measurements were: CI = tissue dry weight (g)/shell length (cm) · 
100], and GSI = gonad weight (g)/somatic weight (g) · 100 (standardized to shell length 
at each sampling period).  Mussels were dissected and frozen, and then dried for 48 hours 
at 60ºC to obtain dry tissue weights (Schiedek et al. 2006). 
Data Analysis 
For each analysis, within-tank means for all mussel growth parameters, GSI, CI, 
and algal clearance rates were calculated. Repeated-measures two-way ANOVAs were 
calculated using the R studio version 0.98.1062 package “ez” to analyze differences in 
parameters at different treatment levels and sub-sample time periods (R Development 
Core Team 2008, Lawrence 2015). Antibiotic treatment levels of both SMX and TRI and 
sampling date were factors, with tank number included as an error term to account for the 
non-independence between temporal samples. The assumption of sphericity was tested 
for each parameter using the Mauchly test and adjusted using Greenhouse-Geisser 
corrections. Normality and homogeneity of variance were assessed through graphical 
inspection of the model residuals, and data were either square-root or log-transformed to 
meet assumptions. Post-hoc multiple pair-wise comparisons between treatment groups 
and sample dates were performed and a Bonferroni correction was applied. For 
parameters in which an interactive effect was significant, an interaction plot was 
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generated and examined for the parameter’s final sampling date. Effects were considered 
significant at or below α=0.05. 
Results 
Mussel growth 
Total percent change in mussel volume was significantly affected by contaminant 
concentration, particularly by SMX level (Table 3.3, Figure 3.1A and B, Figure 3.2A), 
with faster overall growth in control groups (Figure 3.1A, Figure 3.2A). While there was 
also an effect of the sample date on percent change in mussel volume, treatment effects 
were not dependent on sample date, and there was no effect of TRI or interactive drug 
effect (Table 3.3).  
Overall growth in percent change of shell length followed a different pattern over 
time with mussels exposed to contaminants having the greatest increase in length. 
Change in shell length was significantly increased by sample date and TRI * SMX * 
Date, with the interaction of the two drugs increasing percent change in length over time 
(Figure 3.1C and D, Figure 3.2B, Table 3.3). The extent of this percent change in length 
after 12 weeks [0.45 (SE ±0.04) %], however, was less overall than the percent change in 
width [1.39 (SE ±0.06) %] for all treatments (Figure 3.1E and F, Figure 3.2C). Percent 
change in mussel width was significantly suppressed by higher SMX levels, but was not 
significantly affected by levels of TRI concentrations (Table 3.3, Figure 3.1E and F). 
Width percent change was significantly less in the highest (S2) treatment mussels as 
compared to controls by the end of the study (p=0.005).  Percent change in mussel height 
was largely negative over time, but was significantly suppressed by higher SMX levels 
(Table 3.3, Figure 3.1G and H, Figure 3.2D), with lower overall percent change in height 
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in S2 than in control groups (Figure 31.G). Interactively, TRI and SMX significantly 
increased height in the S1-T2 treatment by week 12, but overall SMX elicited the most 
significant suppressive effect (F72, 144 = 8.48, p=<0.001).  
Mussel wet biomass percent change was significantly affected by the interactions 
of SMX * Date (Table 3.3). Week 6 control SMX mussels (S0) had a significantly lower 
percent change in wet biomass than the highest treatment (S2, p=0.049), but by Week 12, 
these same controls had a higher average percent change in mass than the other 
treatments, though not significantly different (Table 3.3, Figure 3.1I, Figure 3.2E). TRI * 
SMX interactions resulted in increased mass in S2-T2 treated mussels by week 12 (Table 
3.3, Figure 3.1I, Figure 3.2E). Condition indices elucidate this further by standardizing 
these mass changes by dry tissue weight and shell length (Figure 3.3A and B). 
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Figure 3.1. The average percent change in mussel growth parameters of total shell 
volume (A and B), length (C and D), width (E and F), height (G and H), and mass (I and 
J) across SMX and TRI treatment groups over the experimental period. Error bars reflect 
± SE of the mean.  
 
 
G
D 
I
E 
H
D 
J
E 
 
37 
 
 
  
 
Figure 3.2. The average percent change in mussel growth parameters of total shell 
volume (A), length (B), width (C), height (D), and mass (E) across all SMX and TRI 
treatment mixtures over the experimental period. Error bars reflect ± SE of the mean.  
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Table 3.3. Repeated-measures ANOVA results for growth factors. Response variables 
were log-transformed (volume) or square-root transformed (L, H, W, Mass). SMX or TRI 
refers to antibiotic concentration levels; significant factors (p< 0.05) are shown in bold.  
Growth 
parameter  
(% change) 
Factor SS MS df F p 
TRI 18.60 9.30 2 1.59 0.211 
SMX 77.59 38.80 2 6.62 0.002 
Sample Date 24.52 12.26 2 19.27 <0.001 
TRI*SMX 8.90 2.22 4 0.38 0.822 
TRI * Sample Date 3.19 0.80 4 1.25 0.292 
SMX * Sample Date 3.79 0.95 4 1.49 0.209 
TRI * SMX * Date 9.25 1.16 8 1.82 0.078 
Error among groups 421.70 5.86 72 
Volume 
Error within groups 91.62 0.64 144 
 
TRI 5.57 2.79 2 4.03 0.021 
SMX 3.75 1.88 2 2.71 0.07 
Sample Date 17.59 8.80 2 134.84 <0.001 
TRI*SMX 2.65 0.66 4 0.96 0.44 
TRI * Sample Date 0.87 0.22 4 3.34 0.012 
SMX * Sample Date 0.27 0.07 4 1.03 0.39 
TRI * SMX * Date 4.31 0.54 8 8.25 <0.001 
Error among groups 49.73 0.69 72 
Length 
Error within groups 9.39 0.07 144 
 
TRI 4.73 2.36 2 0.72 0.490 
SMX 55.61 27.81 2 8.48 <0.001 
Sample Date 1.74 0.87 2 5.16 0.007 
TRI*SMX 30.46 7.62 4 2.32 0.065 
TRI * Sample Date 4.73 1.18 4 7.04 <0.001 
SMX * Sample Date 3.07 0.77 4 4.57 0.002 
TRI * SMX * Date 3.95 0.49 8 2.94 0.005 
Error among groups 236.16 3.28 72 
Height 
Error within groups 24.22 0.17 144 
 
TRI 0.75 0.38 2 0.32 0.724 
SMX 12.71 6.35 2 5.48 0.006 
Sample Date 4.41 2.21 2 12.53 <0.001 
TRI*SMX 6.26 1.57 4 1.35 0.260 
TRI * Sample Date 0.38 0.10 4 0.54 0.706 
SMX * Sample Date 0.87 0.22 4 1.24 0.296 
TRI * SMX * Date 1.41 0.18 8 1.00 0.435 
Error among groups 83.54 1.16 72 
Width 
Error within groups 25.34 0.18 144 
 
TRI 6.32 3.16 2 0.55 0.581 
SMX 2.40 1.20 2 0.21 0.813 
Sample Date 281.06 140.53 2 138.68 <0.001 
TRI*SMX 107.59 26.90 4 4.65 0.002 
TRI * Sample Date 3.15 0.79 4 0.78 0.543 
SMX * Sample Date 12.61 3.15 4 3.11 0.017 
TRI * SMX * Date 11.56 1.44 8 1.43 0.191 
Error among groups 416.47 5.78 72 
Mass 
Error within groups 145.92 1.01 144 
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Feeding Rates 
At most sample periods, feeding rates were not significantly affected by experimental 
parameters, except for sample date (Table 3.4). Algal clearance rates by control mussels 
were significantly higher than treatment mussels of aggregated SMX levels only on 
experimental Day 30 [S0: 0.25 (SE 0.03) cells mL-1 min-1 versus S1: 0.17 (SE 0.03) cells 
mL-1 min-1 and S2: 0.16 (SE 0.02) cells mL-1 min-1, F2,24 = 5.14, P = 0.013 ]. 
 
Body condition: Gonado-somatic Index & Condition Index 
The mean tank condition index (CI) was affected by both SMX and TRI treatment 
levels over time. Mean CI significantly decreased from week 6 to week 12 in the highest 
treatment concentrations of SMX and TRI, while it increased for control groups and 
lower treatment concentrations (Figure 3.3A and E). The following factors significantly 
influenced CI: TRI levels, SMX levels, interactions of TRI * Sample Date, SMX * 
Sample Date, and TRI * SMX * Date (Table 3.4, Figure 3.4A and E). The interaction of 
SMX and TRI treatments suppressed CI in mixture treatment levels as compared to the 
treatment concentrations without TRI.  
The gonado-somatic index (GSI) of mussels (standardized to mussel length) was 
significantly influenced by TRI and the interaction of TRI * SMX (Figure 3.3C and D, 
Table 3.4). Interactively, the highest levels of TRI and SMX resulted in higher GSI at 
week 12. The week 6 GSI:length index was significantly higher in control treatment and 
treatments with SMX only than those treated with any concentration of TRI (Figure 
 
40 
3.3B). Week 12 GSI:length exhibited higher mean GSI:length values for control S0 
mussels than S2 treated mussels, though not significantly (Figure 3.3C).  
 
A 
C 
B 
D 
a 
b 
b 
a 
b 
c 
a 
a 
b 
 
41 
 
Figure 3.3. Mean mussel tissue indices at weeks 6 and 12 in response to antibiotic 
treatments for A) CI by SMX level, B) CI by TRI level, C) GSI by SMX level, D) GSI by 
TRI level, D) CI by SMX and TRI mixtures and E) GSI by SMX and TRI mixtures. 
Lowercase letters and asterisks (*=different than control) represent significant 
differences, p<0.05.  
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Table 3.4. Repeated measures ANOVA results for mean tank body condition indices (CI 
and GSI) and algal clearance rates, including 2nd, and 3rd order interactions. Response 
variables were log-transformed. SMX or TRI refers to antibiotic concentrations; 
Significant factors and p-values < 0.05 are shown in bold.  
Dependent 
variable  Factor SS MS df F p 
TRI 3.04E-05 1.52E-05 2 8.90 <0.001 
SMX 6.65E-05 3.33E-05 2 19.46 <0.001 
Sample Date 1.38E-06 1.38E-06 1 0.73 0.396 
TRI*SMX 1.02E-05 2.55E-06 4 1.49 0.218 
TRI * Sample Date 2.90E-05 1.45E-05 2 7.69 0.001 
SMX * Sample Date 4.84E-05 2.42E-05 2 12.82 <0.001 
TRI * SMX * Date 2.65E-05 6.63E-06 4 3.51 0.013 
Error among groups 9.23E-05 1.71E-06 54 
 
 
Condition 
Index  
(CI) 
Error within groups 1.02E-04 1.89E-06 54 
 
TRI 3.68E-04 1.84E-04 2 5.02 0.010 
SMX 5.27E-05 2.63E-05 2 1.80 0.175 
Sample Date 1.89E-05 1.89E-05 1 0.17 0.679 
TRI*SMX 6.17E-05 1.54E-05 4 2.94 0.028 
TRI * Sample Date 3.73E-05 1.87E-05 2 2.67 0.079 
SMX * Sample Date 8.61E-07 4.31E-07 2 0.06 0.940 
TRI * SMX * Date 2.97E-05 7.43E-06 4 1.06 0.384 
Error among groups 2.83E-04 5.24E-06 54 
 
 
Gondo-somatic 
index  
(GSI) 
Error within groups 3.78E-04 7.00E-06 54 
 
TRI 0.05 0.02 2 0.24 0.793 
SMX 0.03 0.02 2 0.18 0.837 
Sample Date 1.13 0.23 5 9.35 <0.001 
TRI*SMX 0.24 0.06 4 0.62 0.656 
TRI * Sample Date 0.12 0.01 10 0.50 0.887 
SMX * Sample Date 0.21 0.02 10 0.88 0.557 
TRI * SMX * Date 0.35 0.02 20 0.73 0.784 
Error among groups 11.97 0.67 18 
 
 
 
 
 
Clearance rate 
Error within groups 1.73 0.02 90 
 
 
 
Discussion 
Long-term (3 month) exposure to antibiotic mixtures at environmentally-relevant 
concentrations affected mussel growth rates and body condition. Although results 
indicate that mussel algal clearance rates were not affected by low concentrations of 
antibiotics, the growth metrics indicate a reduced ability of the mussels to assimilate their 
algal feed. Specifically, whole-body metrics of fitness such as total shell volume and 
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biomass growth rates, as well as body condition indices, were significantly affected over 
the course of several months. Total percent change in shell volume, an aggregate measure 
of each mussel’s length, width, and height, was significantly suppressed by the highest 
SMX treatments. Previous research has found that mussels tend to become narrower 
(longer and less wide) under conditions of high density and at low food availability, but 
food and density levels were consistent across treatments in this experiment (Alunno-
Bruscia et al. 2001). Thus, the suppression in shell volume growth rate observed, and the 
strongly suppressed width over time (which significantly diverged from controls in the 
highest aggregated SMX treatment but was unaffected by TRI parameters), indicates that 
antibiotic treatments may have imposed disruptions in food assimilation, possibility due 
to disturbance of the mussel gut digestion microbiome (mimicking lack of food). 
Possible disruptions in the gut digestion microbiome are corroborated by the fact 
that mean condition index decreased in the high SMX treatment levels in the latter half of 
the study. Though SMX levels are the primary driver of effects in this mixture study, 
there were interactive effects between SMX and TRI for a number of parameters - both 
body condition and growth dimensions. Condition index was sensitive to both SMX and 
TRI, with suppressive interactive effects found with both drugs and across sample dates. 
GSI on the other hand, was affected by TRI levels and positively influenced by the 
interaction of TRI * SMX. Moreover, though change in shell volume was driven by SMX 
level, the individual morphological components (length, width, and height) exhibited 
differential sensitivities to these mixture concentrations. This indicates that mixture 
studies that include measurements across diverse growth dimensions are vitally 
important, as such studies more closely mimic real-world exposures and the array of 
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potential effects exhibited due to the variability caused by drugs of the same class with 
different target sites. 
SMX may have had a greater influence on mussel growth than TRI due to the 
potential increased toxicity of the photo-degradation products of SMX in seawater (Trovó 
et al. 2009b). Both SMX and TRI are not readily biodegradable in seawater, but they 
transform through photo-degradation with a half-life of approximately 42 days for 
trimethoprim and 21 days for sulfonamide drugs (Benotti and Brownawell 2007, 2009, 
Kümmerer 2008, Larcher and Yargeau 2012). Previous research shows that photo-
degradation products may have a greater toxicity than the parent molecule. Two studies 
by Trovó et al. (2009a and 2009b) found that the toxicity of SMX increased over the 
course of the test periods, with the authors concluding that the toxicity of the SMX photo-
transformation products generated were higher than that of the original compound. 
Trimethoprim photo-degradation studies in saltwater indicate “only a small increase” in 
the toxicity on test organisms, with intermediates which were moderately toxic for the 
organisms tested (Sirtori et al. 2010, Fatta-Kassinos et al. 2011). Thus SMX is degrading 
more quickly (with its shorter half-life), and potentially with more toxic degradation 
products. Assessments of sub-lethal effects of transformation products must be included 
in the suite of pharmaceutical contaminant research to more closely simulate 
environmental conditions. 
As efficient filter feeders, mussels in both laboratory and field studies have 
demonstrated bioaccumulation of pharmaceuticals (Benotti and Brownawell 2007, 
McEneff et al. 2014). Antibiotics such as SMX and TRI find their way into the 
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environment mainly through effluent of wastewater treatment plants, and are considered 
“pseudo-persistent” due to their continued release into the environment (González-Pleiter 
et al. 2013). In laboratory settings, mussel sub-cellular endpoints such as genotoxic and 
immunotoxic metrics have responded to a suite of pharmaceuticals, including antibiotics 
(Gagné et al. 2006, Lacaze et al. 2015). Our findings support the indication of suppressed 
health characteristics of mussels facing exposure to antibiotics. This study offers an 
understanding of how a benthic foundational intertidal species responds to the presence 
of SMX and TRI in the water (and likely bioaccumulation in the tissue) over the long-
term using whole-organism growth rates and body condition indices, and offers insight 
on environmental effects of pharmaceutical contaminants, and specifically the suite of 
antibiotics, that are released into marine ecosystems.  
M. californianus, is recognized as a foundation species on the Pacific coast 
because it creates extensive beds that provide habitat, food and refuge for a wide range of 
coastal organisms that live on exposed rocky shores (Suchanek 1992, Gaylord et al. 
2011). As foundational species in rocky intertidal and subtidal ecosystems, changes in 
mussel growth, condition, and reproduction could have profound effects on marine 
coastal communities. This mussel plays an important role as a dominant competitor over 
much of its range, as it excludes other competitors from accessing primary substrate 
(Paine 1966, Gaylord et al. 2011). As such, Gaylord et al. 2011 note that “biological 
diversity of many intertidal communities is linked tightly to the ecological performance 
of this bivalve.” Therefore, if these important filter feeders are being exposed to 
pharmaceuticals (from wastewater effluent or through other pathways), and the drugs are 
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affecting their growth and condition parameters, shifts in overall population abundance 
may occur, which could have wide-ranging community-level effects. 
Global human population is rapidly growing, people are increasingly using 
pharmaceutical drugs, and coastal areas are home to 41% percent of the world population 
(Gaw et al. 2014, Gu et al. 2010). Along with over-exploitation, habitat loss, and invasive 
species, contaminants are one of the many identified anthropogenic stressors to the 
coastal marine environment (Fabbri and Franzellitti 2015). Thus, important coastal 
marine foundation species such as M. californianus mussels may become increasingly 
vulnerable to pharmaceutical contaminants as these trends continue. Yet, there is still 
much to be explored in long-term studies examining effects of the cocktail of 
pharmaceuticals released into ocean waters to understand interactive and cumulative 
organismal and potential ecosystem-level effects (Boxall 2004).  This research 
contributes to the understanding of the effects on marine mussel growth and condition in 
response to long-term drug exposure to inform these potential ecosystem-level effects. 
The ever-growing level of prescription drug consumption and the diverse array of drug 
classes present in these habitats necessitates mixture studies to inform source 
management and forestall a long-term largely irreversible contamination load in our 
marine ecosystems. 
 
47 
Chapter 4: Conclusions 
 
Assessing how species across interacting trophic levels of an intertidal system 
respond to the presence of sulfamethoxazole and trimethoprim in the water offers 
important information on the environmental effects of anthropogenic pharmaceutical 
contaminants, and specifically the suite of antibiotics, that are released into marine 
ecosystems. Photosynthetic primary producer populations (marine microalgae) are 
suppressed in the presence of environmentally-relevant concentrations of these drugs, 
thus there is potential for cascading effects in food webs. Additionally, body condition 
index, growth rate, and reproductive indicators are significantly affected by these 
substances in benthic foundation species (e.g., marine mussels). The implications of this 
research contribute directly to the data gaps surrounding pharmaceutical contaminants in 
that it addresses long-term effects of these emerging contaminants at low-level, mixture 
exposures by marine organisms.1  
At this stage, there is a need for further study on the effects of many classes of 
pharmaceuticals on a wide array of marine organisms (Gaw et al. 2014), but next steps 
could include systematic approaches to assess higher ecosystem-level effects. Short-term 
acute ecotoxicology studies likely will not reveal the non-monotonic effects that are 
observed over the long-term at low concentrations of drugs. I recommend a study 
approach involving first the identification of the most prevalent pharmaceutical drugs in 
different classes found within coastal and estuarine environments utilizing occurrence 
data, and then in a laboratory setting, systematic assessments of the long-term effects of 
these most prevalent drugs on growth and reproduction of a suite of potentially sensitive 
                                                
1 To access any original raw data from this study, please email JaclynRTeixeira@gmail.com 
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target organisms, individually and in combination. Previous research shows that 
unicellular and structurally simplistic organisms are especially sensitive to 
pharmaceutical contaminants, so I would recommend that, in the marine environment, 
there should be a focus on planktonic primary producers, or larval life stages of 
invertebrates, as non-target organisms potentially sensitive to these drugs (Isidori et al. 
2005, El-Bassat et al. 2012). Additionally, the potential for increased toxicity of photo-
degradation products of prevalent pharmaceuticals should be investigated rigorously in a 
chemistry and ecotoxicological setting, which will inform ecological studies of the effects 
of these on marine organisms resulting from long-term exposures. 
The potential for antimicrobial-resistant microorganisms (and resultant effects on 
organism health) due to environmental exposure to antibiotic contaminants is another 
critical concern (Boxall et al. 2012). The World Health Organization (WHO) has 
identified the emergence of antimicrobial resistance as one of the serious concerns for 
health policies in the future (WHO (World Health Organization) 1998). Byrne-Bailey et 
al. (2009) found the establishment of resistant genes in bacterial isolates from 
sulfonamide antibiotic-contaminated manured agricultural soils and pig slurry, while 
Gaze et al. (2011) measured differences in bacterial gene prevalence in sewage-exposed 
sludge and concluded that “current waste disposal practices may present a significant risk 
to human health by recycling antibiotic resistant genes of human and animal origin to the 
wider environment” (Byrne-Bailey et al. 2009, Gaze et al. 2011).  In Mytilus edulis 
mussels, antibacterial agents used in aquaculture caused a proliferation of resistant 
bacteria in mussels at higher levels in samples taken at the farm after medication than 
before or in control areas (Ervik et al. 1994).  However, it is noted that many questions 
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remain in identifying the role pharmaceutical antibiotic contaminants play in antibiotic 
resistance, as information is limited to a narrow window of antibiotic classes in certain 
environments (Boxall et al. 2012). Antibiotics in the environment may result in resistant 
strains of bacteria, and if humans are exposed to these resistant bacteria, there may be 
impacts to human health.  
This study takes a step towards informing management and policy of the 
potentially harmful, anthropogenically-sourced pharmaceuticals, and their handling 
techniques. Preventing further contamination is an important step in managing emerging 
pharmaceutical contaminant effects. This can be achieved, in part, by informing the 
public that disposing of unwanted drugs in the toilet or in landfills is harmful to the 
environment, and that pharmaceuticals should instead be taken to approved drop-off 
points (i.e., police stations in Oregon) for proper handling. At the time of writing, the 
Food and Drug Administration’s (FDA’s) website recommends on their page titled “How 
to Dispose of Unused Medicines” to first try to locate proper drop-off locations, but if 
that is not possible, to throw the drugs away in plastic bags in the trash, or, if the drugs 
are especially powerful or dangerous, to get rid of them immediately through flushing 
down the toilet (U.S. Food and Drug Administration 2016, U.S. Food and Drug 
Administration (FDA) 2016). FDA environmental assessment expert, Dr. Raanan Bloom 
is quoted: “While FDA and the Environmental Protection Agency take the concerns of 
flushing certain medicines in the environment seriously, there has been no indication of 
environmental effects due to flushing” (U.S. Food and Drug Administration 2016).  
Concurrently, the Oregon Department of Environmental Quality’s (Oregon DEQ) website 
states a very different message: “Unused drugs kept in medicine cabinets, tossed in the 
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garbage, or flushed down the toilet or drain can be serious threats to human and 
environmental health”(Oregon Department of Environmental Quality 2016).  I 
recommend that these mixed messages to the public should be resolved: the FDA should 
review the latest science and update their recommendations, and an easily accessible 
database should be created linking to lists of designated collection sites for each state and 
Drug Take-Back events (periodically sponsored by the US Drug Enforcement Agency). 
Stakeholders including wastewater management boards and prescription drug disposal 
sources such as hospitals should be involved in order to spark conversation in identifying 
improved handling techniques of the drugs. 
Coastal areas contain over 41% percent of the world population (approximately 
2.3 billion people), and more than 50% of coastal countries have 80–100% of their total 
population within 100 km of the coastline (Gaw et al. 2014). In addition, the use of 
prescription drugs among people is rapidly increasing (Gu et al. 2010). Thus, coastal 
marine and estuarine ecosystems may become especially vulnerable areas to 
pharmaceutical contaminants as these trends continue. The ever-growing level of 
prescription drug consumption necessitates studies to examine the environmental effects 
of various classes of drugs present in these habitats to form the scientific basis on which 
the reevaluation of source management may occur, in order to forestall a long-term 
largely irreversible contaminant load in our marine ecosystems. 
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